[A study of neoadjuvant chemotherapy in the treatment of cancer of pyriform sinuses]. / Papel de la quimioterapia neoadjuvante en el tratamiento del carcinoma de seno piriforme.

We present a retrospective study of 49 cases of squamous cell carcinoma of the pyriform sinus treated with induction chemotherapy (group I) and compared with 103 cases that did not received this treatment (group II). Thirty four patients were treated with combined cis-platinum and 5-fluoracil. Local and regional control and distant metastasis were analyzed, and no differences between the two groups were found. Five-year global actuarial survival rates were 23% in group I, and 35% in group II (p = no significant). In group I, those cases that responded to chemotherapy had a better 4-year survival rate (33%) than those who did not (7%) (p < 0.1). When patients who underwent radical radiotherapy were analyzed, a better 5-year survival rate was found in group I (41%) versus group II (13%) (p < 0.05).

[Results of radiotherapy in 117 cases of carcinoma of pyriform sinuses]. / Resultados del tratamiento radioterápico en 117 casos de carcinoma de seno piriforme.

A retrospective study was made of 117 cases of squamous cell carcinoma of the pyriform sinus treated with radiation therapy (RTX). Sixty-three patients underwent radical RTX (group I) and 54 patients received combined treatment (group II). Adjuvant chemotherapy (QTX) was applied in 36 patients (27 of group I, 9 of group II). Residual disease after treatment was observed in 35% (group I) and 4% (group II) (p < 0.001). The rates of local and/or regional recurrence were 46% and 38% respectively. Distant metastases were found in 6% (group I) and 20% (group II) (p < 0.05). The 5-year actuarial survival rates were 23% (group I) and 35% (group II). The group I patients who received QTX had better survival rates (41%) than those who did not (13%) (p < 0.05). The group II survival was not improved by QTX.